 Coeptis Therapeutics Inc OTC: COEP has entered into a strategic agreement with Statera Biopharma Inc NASDAQ: STAB that gives Coeptis the right to acquire Staterastoll-like receptor 5 TLR5 agonist platform, including entolimod. Coeptis will agree to pay. 